Hopes that anti-tau drugs could emerge as treatments for Alzheimer’s have been dented by the failure of a phase 2b trial of J&J’s posdinemab.
CMS innovation center to expand team focused on drug prices
To help with new pilot models aimed at lowering drug costs across Medicaid and Medicare, CMS’ innovation center is ramping up staff. “We are on



